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Abstract
Background
Patient retention in chronic HIV care is a major challenge following the rapid expansion of
combination antiretroviral therapy (cART) in Ethiopia.
Objective
To describe the proportion of patients who are retained in HIV care and characterize predic-
tors of attrition among HIV-infected adults receiving cART in Addis Ababa.
Method
A retrospective analysis was conducted among 836 treatment naïve patients, who started
cART between May 2009 and April 2012. Patients were randomly selected from ten health-
care facilities, and their current status in HIV care was determined based on routinely avail-
able data in the medical records. Patients lost to follow-up (LTFU) were traced by telephone.
Kaplan-Meier technique was used to estimate survival probabilities of retention and Cox
proportional hazards regression was performed to identify the predictors of attrition.
Results
Based on individual patient data from the medical records, nearly 80% (95%CI: 76.7, 82.1)
of the patients were retained in care in the first 3 and half years of antiretroviral therapy.
After successfully tracing more than half of the LTFU patients, the updated one year reten-
tion in care estimate became 86% (95% CI: 83.41%, 88.17%). In the multivariate Cox
regression analyses, severe immune deficiency at enrolment in care/or at cART initiation
and ‘bed-ridden’ or ‘ambulatory’ functional status at the start of cART predicted attrition.
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Conclusion
Retention in HIV care in Addis Ababa is comparable with or even better than previous find-
ings from other resource-limited as well as EU/USA settings. However, measures to detect
and enroll patients in HIV care as early as possible are still necessary.
Introduction
The advent of combination antiretroviral therapy (cART) has been accompanied by prolonged
survival and improved quality of life among HIV infected persons worldwide, including
resource-limited settings [1–5]. For instance, AIDS mortality has reduced by more than half
within 5 years after cART became widely available in Addis Ababa, Ethiopia [6]. In addition,
the number of new HIV infections is gradually decreasing as evidenced by a reduction in the
national adult HIV incidence from 0.28% per year in 2004 to 0.03% per year in 2014 [7, 8].
However, poor retention in HIV care after patients started cART is recognized as a major
challenge [9, 10]. Conceptually, retention in care and attrition complement each other, and
current literature provides various, but closely related definitions [11–15]. The former gener-
ally refers to the proportion of cART taking patients known to be alive and still receiving medi-
cal care either on-site or at another site, including those stopping ARV medications (because of
medical or personal reasons) while remaining in care. Attrition is defined as not being seen at
the ART clinic for at least 1 month following patient’s most recent planned clinic visit or phar-
macy refill appointment for reasons related to death or lost to follow-up (LTFU). Poor reten-
tion in care, particularly related to LTFU, can be devastating for patients’ lives, and also
facilitates the occurrence of virologic failure, which in turn could lead to an increased chance of
HIV transmission [16–19]
Previous studies about retention in care in Addis Ababa were conducted in the early years
of roll-out of cART, when the program was not yet fully formed and there was limited experi-
ence to retain all the patients who initiated cART in HIV care [9, 13]. The present study is con-
ducted to estimate the current retention in care and to identify predictors of attrition, which
may help health care practitioners, program managers and policy makers to improve the man-
agement of HIV-infected people on cART.
Method
Setting and study participants
This study was conducted between September 2012 and April 2013 in ten randomly selected
health care facilities that had started providing adult cART service as of January 1, 2009 or
before in Addis Ababa, Ethiopia. At the time of the study, HIV-infected adults who fulfilled the
following World Health Organization (WHO) criteria were automatically eligible for cART
once their readiness to initiate anti-retroviral therapy was assured: WHO clinical stage IV, irre-
spective of CD4 cell count; WHO clinical stage III with a CD4 cell count of350/mm3; all
WHO clinical stages with CD4 cell counts200/mm3 [20]. Patients eligible to participate were
selected in a two-step procedure using the national ART register as a sampling frame. First, we
selected all adult HIV-infected persons without previous exposure to cART—except for the
prevention of mother to child transmission—who initiated cART between May 1, 2009 and
April 30, 2012. Patients who had been transferred-in or formally transferred-out after initiating
cART were excluded. Second, out of these patients, we selected every 8th patient from the ART
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register using a systematic random sampling technique. Fig 1—Flowchart depicting the ran-
dom selection of health care facilities and patients included in the study—illustrates the selec-
tion process.
Ethical consideration
Ethical approval was obtained from the Institutional Review Boards (IRB) at the College of
Health Sciences, Addis Ababa University, and Millennium Medical College, St. Paul Hospital.
Patients who were alive and still receiving medical care gave informed verbal consent. Verbal
consent was preferred (over written consent) because a substantial proportion of the study par-
ticipants were illiterate. Also, given the very sensitive nature of being HIV-positive in Ethiopia,
obtaining a written consent (via signature or finger prints) could have potentially violated
patients' privacy and anonymity. For patients who were not-retained in care, consent for trac-
ing had already been obtained at start cART as part of the routine clinic follow-up and
Fig 1. Flowchart depicting the random selection of health care facilities and patients included in the study.
doi:10.1371/journal.pone.0130649.g001
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pharmacy refill procedures. Data were retrieved anonymously from medical registers using
patients’ unique ART number or medical record number.
Outcome measures
The current status in HIV care of each selected patient was determined based on the informa-
tion in the ART register or patient follow-up card. It was typically recorded as died (of any
cause), lost, dropped, stopped or retained in care. A patient defined as “lost” had missed his or
her next clinic or pharmacy refill appointment for at least 1 month and at most 3 consecutive
months. A patient defined as “dropped” had missed his or her planned clinic or pharmacy refill
appointment for more than 3 consecutive months. Patients known to be alive and retained in
care, but temporarily discontinued taking cART due to medical or personal reasons were
defined as “stopped”. Patients were defined as ‘retained in care’ if they were alive and known to
be still receiving medical care at the time of the study, including those considered as “stopped.”
Attrition was defined as the number of patients documented as died, lost or dropped. Both
patients who had been lost or dropped were considered as LTFU.
Independent variables
Socio-demographic variables at enrolment in HIV care including age, sex, marital status, reli-
gion, educational level, and HIV-status disclosure were considered as potential predictors of
attrition. The following variables were considered as additional predictors: dates of HIV diag-
nosis, enrolment in HIV care and cART initiation, type of antiretroviral treatment regimen,
and evidence of tuberculosis at or after start cART. In addition, WHO clinical stage, functional
status, CD4 cell count, and hemoglobin level were collected from the intake form or follow-up
card. The following variables were also included in the analysis: time since start cART at study
entry (‘date of the last known clinic or pharmacy refill visit’minus ‘date of cART initiation’),
and time since HIV diagnosis at start cART (‘date of cART initiation’minus ‘date of HIV
diagnosis’).
Data extraction from the medical records
Patient data were extracted from the medical records using a Case Report Form (CRF) by data
clerks. Contact addresses of all patients who had been lost or dropped were collected by the
first author, which were later used for tracing purposes. Deaths already known by the ART
clinic during the routine follow-up care were collected from the medical records. For patients
who had died or become LTFU, dates of the last known clinic or pharmacy refill visit were
recorded.
Tracing of LTFU patients
In the participating facilities, it is a routine practice that patients who become LTFU are traced
by adherence case managers and data clerks using telephone contacts.
In the present study, tracing of LTFU patients was carried out by the first author. First, all
LTFU patients eligible for tracing were identified from the ART register. Next, patients’ or
their caretakers’ telephone number together with information about whether the patient had
disclosed his/her HIV status or not and to whom were extracted from the intake form.
Up to three attempts to contact LTFU patients by phone were made to ascertain their cur-
rent status. When the patient himself/herself answered the call, he/she was first informed that
the phone call was from the health facility where he/she initiated treatment, and he/she was
kindly asked whether the timing was convenient. When the patient responded positively
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(otherwise an appointment was made for another round of call) he/she was asked the reasons
for staying away, without mentioning anything about HIV/AIDS or cART until a confidential-
ity was established. In addition, they were asked if currently accessing any follow-up medical
care, and when replied yes, they were requested to name the health facility for anti-retroviral
drug refill, the re-start date, and whether they had discontinued cART in between; LTFU
patients who named a legitimate ART site were generally re-classified as ‘retained in-care.’ For
patients confirming not accessing any medical care, possible reasons for discontinuation of
cART were explored further and recorded. In these cases, patients were advised to re-start
medical care as quickly as possible. When a proxy informant (family member or friend)
answered the phone call, s/he was kindly asked about the current address of the LTFU patient,
and depending on the response, patient’s current vital status (alive or dead) was ascertained.
LTFU patients who were reported as dead or confirmed to be truly LTFU were considered as
“not-retained in care.” Patients who did not answer phone calls, those whose current vital sta-
tus was ascertained via proxy informants, and those with no, non-functioning or a wrong tele-
phone number were assumed to be “not-retained in care” in one analysis option, and “retained
in care” in an alternative analysis. The status on chronic HIV care of all other patients was
taken from the medical records.
Statistical analyses
Retention in HIV care was the primary outcome of interest, and it was estimated using three
different, but closely related analytic approaches. First, it was calculated as the number of
patients known to be alive and receiving cART at the time of the study, including patients con-
sidered as “stopped,” divided by the total number of patients who started cART. This calcula-
tion was based on individual patient data routinely collected and available in the medical
records. In the second approach, patients who were formally documented to be LTFU, but
were successfully traced and claimed to be accessing medical care elsewhere with-out the
knowledge of the facility where they had initiated cART (“self-transferred”) were re-classified
as ‘retained in care’ and added to the numerator. In this approach, all untraceable LTFU
patients were assumed “not-retained in care.” Analyses to identify predictors of attrition are
based on estimates of this second approach. The third analytic approach was identical to the
second approach, except that untraceable LTFU patients were assumed to be ‘retained in care’
and added to the numerator.
Time-to-attrition was the other end point of the study. It was calculated (in months) as the
difference between the dates of cART initiation and the last known clinic or pharmacy refill
visit. For all time-to-attrition analyses, time zero was set at the date of cART initiation. All-
cause attrition was established at the recorded or reported date of death, last known date of
clinic/or pharmacy refill visit, or final study date (April 30, 2013). Follow-up time for LTFU
patients who were successfully traced and claimed to be “self-transferred” was censored at the
date of phone call tracing.
Since the WHO immunological criteria (with/or without clinical staging) is commonly used
for assessing eligibility to initiate cART in Addis Ababa [20], survival probabilities of retention
in care stratified by this variable was estimated using the Kaplan-Meier method. The log-rank
test was used to compare probability estimates of retention in care between the survival curves.
Cox proportional hazards regression was performed to identify the variables that predicted
post-cART attrition. The Hazard Ratio (HR) in the Cox regression model estimates the relative
likelihood of attrition at consecutive points in time after cART initiation.
Predictor variables with a p-value of<0.2 were first identified in a univariate Cox regression
analyses. Then, a multivariate Cox regression model was fitted by adding back in to the model,
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one at a time, variables not selected at a previous step. Likelihood ratio tests were used to com-
pare between the fit of various models. Finally, variables that significantly (P-value<0.05) pre-
dicted attrition were kept in the final model. Proportional hazards assumption was checked by
Schoenfeld-tests of residuals. EPI-data version 3.1 was used for data-entry and SPSS version 17
and STATA version 11 for statistical analyses.
Results
Patients
Characteristics of patients are summarized in Table 1. Of the total 870 eligible patients, 34
declined participation, and 836 patients were included in the present analyses. At enrolment in
care, the median CD4 cell count was 141 (IQR, 73–239) cells/μL, and 203 (24.5%) patients
were in WHO clinical stage I, 245 (29.6%) in stage II, 293 (35.3%) in stage III, and 88 (10.6%)
in stage IV condition. In addition, 631 (79.6%) patients had a working functional status, 137
(17.3%) ambulatory, and 25 (3.2%) were bed-ridden.
Patients’ status in HIV care after cART initiation
As of April 30, 2013, 665 (79.5%; 95% CI: 76.7, 82.1) alive patients, including 1 ‘stopped’ case,
were registered as retained in care, while 55 (6.6%), 11 (1.3%) and 105 (12.6%) were initially
recorded as died, lost and dropped, respectively. Of the 116 LTFU patients, 65 (56%) were suc-
cessfully traced: 31 were confirmed as truly LTFU, 19 claimed that they had been “self-
transferred” after having had discontinued cART from 1 week to 22 months, and 15 patients
were reported to have died of an unidentified, but illness-related cause, within 1 to 6 months of
their last clinic/or pharmacy refill visit. The most frequently mentioned reasons for being
LTFU included being away from home for various reasons (n = 12), searching for religious
cure/holy water use (n = 6), lack of family support (n = 3), ‘no substantive reasons’ (n = 2), feel-
ing healthy (n = 2), fear of health care providers’ reaction to patient’s return to HIV care
(n = 1), fed-up with taking antiretroviral drugs (n = 1), fear of drug side effects (n = 1), and
stigma/discrimination (n = 1). Two patients refused to provide further details. Of the remain-
ing 51 “LTFU patients” whom we were unable to trace, 21 had non-functioning telephone
numbers, 15 had no recorded contact address, 6 had given a wrong telephone number, and 1
patient did not answer the phone call. In addition, proxy informants of 8 LTFU-patients said
that these patients were alive and currently living far from the study area.
Estimating retention in care after cART initiation
Using individual patient data in the medical records, 79.5% (95% CI: 76.7, 82.1) were initially
classified as retained in care by April 30, 2013. After successfully tracing 65 out of 116 LTFU
patients, and assuming that the remaining 51 untraceable patients were ‘truly LTFU’, the
updated retention in care estimate increased to 81.8% (95% CI: 79.1, 84.3) in the first 3 and
half years of cART. With this estimate, the median time to attrition was 5 (IQR, 0 to 10)
months while the median time between patients’ last known clinic visit and date of tracing was
16 (IQR, 8.3 to 26) months. The cumulative proportion of patients retained at 6, 12, 24, and 36
months after cART initiation was 90.67% (95% CI: 88.49%, 92.46%), 85.97% (95% CI: 83.41%,
88.17%), 82.70% (95% CI: 79.84%, 85.19%), and 79.04% (95% CI: 75.57%, 82.08%), respec-
tively. With the alternative assumption that the 51 untraceable LTFU patients were “self-trans-
ferred”, the retention in care estimate further increased to 87.9% (95% CI: 85.5, 89.9) at the end
of the current analysis.
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Table 1. Patients’ socio-demographic, clinical, and treatment characteristics (n = 836).
Patient characteristic Value*
Age—yearsa, mean (SD) (n = 833) 35 (8.9)
Sex—malea 324 (38.8%)
Educational statusa, (n = 795)
No education 112 (14.1%)
Primary 267 (33.6%)
Secondary 330 (41.5%)
Tertiary 86 (10.8%)
Marital statusa, (n = 796)
Never married 186 (23.3%)
Married or cohabiting 381 (47.9%)
Divorced or separated 136 (17.1%)
Widowed 93 (11.7%)
Religiona, (n = 795)
Christian 741 (93.2%)
Muslim 51 (6.4%)
Other 3 (0.4%)
Substance use/misuse—yesa, (n = 686) 144 (21.0%)
Body Mass Index (kg/m2)a, mean (SD) (n = 419) 20.6 (3.38)
Employment statusa, (n = 617)
Unemployed 199 (32.3%)
Not working/studying due to ill health 73 (11.8%)
Working full time 299 (48.5%)
Working part time 46 (7.5%)
HIV status disclosure (to family/friend/neighbor)—yesa, (n = 612) 572 (93.5%)
Functional statusb, (n = 817)
Working 677 (82.9%)
Ambulatory 113 (13.8%)
Bed ridden 27 (3.3%)
WHO clinical stageb,d, (n = 830)
Stage I 191 (23.0%)
Stage II 231 (27.9%)
Stage III 309 (37.2%)
Stage IV 99 (11.9%)
First line drug regimenb
TDF-containing 434 (51.9%)
AZT-containing 322 (38.5%)
d4T-containing 80 (9.6%)
CD4 cells/μLb, median (IQR) (n = 828) 133.5 (72-to-203)
Hemoglobin (g/dL)b, mean (SD) (n = 709) 13.1 (2.2)
Evidence of tuberculosis at or after start cART—yes, (n = 817) 151 (18.5%)
Months since HIV diagnosisb, median (IQR), (n = 822) 1 (0-to-7)
Months since start cARTc, mean (SD), (n = 836) 22.6 (12.5)
* values are n (%) unless otherwise indicated.
a at enrolment in HIV care.
b at start cART.
c at study entry or at last known clinic/pharmacy refill visit date.
d according to the revised World Health Organization clinical staging of HIV/AIDS for adults and
adolescents, 2005 [51].
TDF, Tenofovir; AZT, Zidovudine; d4T, Stavudine.
SD, standard deviation; IQR, inter-quartile range.
doi:10.1371/journal.pone.0130649.t001
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Retention in care versus CD4 cell count and functional status at start
cART
Of the total 828 patients with a recorded CD4 cell count at the start of cART, 57 had died or
become LTFU in quartile 1 (72 CD4 cells/μL), 36 in quartile 2 (73–133 CD4 cells/μL), 28 in
quartile 3 (134–202 CD4 cells/μL), and 26 in quartile 4 (203 CD4 cells/μL). The Kaplan-
Meier survival curve in Fig 2 –Kaplan-Meier survival curve of retention in HIV care by quar-
tiles of CD4 cell count (cells/μL) at the start of cART—shows that patients who started cART
in quartiles 4, 3, and 2 appeared more likely to be retained in care than patients in quartile 1
(log-rank Chi-sq statistic = 30.8, df = 3, p-value<0.001). In addition, patients with ‘bed-ridden’
or ‘ambulatory’ functional status at start cART had significantly lower probability of being
retained in care than patients with a ‘working’ functional status (log-rank Chi-sq statis-
tic = 24.53, df = 2, p-value<0.001; Fig 3 –Kaplan-Meier survival curve for retention in HIV
care by functional status at the start of cART).
Predictors of attrition from care
Results of the univariate and multivariate Cox regression analyses for predictors of attrition are
presented in Table 2. The following variables assessed at enrolment in care had a substantial
proportion of missing values and were therefore not entered in the multivariate analyses:
employment status (n = 617), substance use/misuse (n = 686), body mass index (BMI)
(n = 419), and hemoglobin level at start cART (n = 709).
Based on the 81.8% retention in care estimate, CD4 cell count at enrolment in care (quar-
tile1 vs. quartile4: HR = 3.03, 95%CI: 1.76, 5.22; quartile2 vs. quartile4: HR = 1.78, 95%CI: 1.00,
3.16; quartile3 vs. quartile4: HR = 1.51, 95%CI: 0.83, 2.75)/or at cART initiation (quartile1 vs.
quartile4: HR = 2.18, 95%CI: 1.33, 3.57; quartile2 vs. quartile4: HR = 1.41, 95%CI: 0.84, 2.38;
Fig 2. Kaplan-Meier survival curve of retention in HIV care by quartiles of CD4 cell count (cells/μL) at
the start of cART, Addis Ababa, 2013 (n = 836).
doi:10.1371/journal.pone.0130649.g002
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quartile3 vs. quartile4: HR = 1.04, 95%CI: 0.59, 1.82) and functional status at start cART (bed-
ridden vs. working: HR = 2.22, 95%CI: 1.10, 4.46; ambulatory vs. working: HR = 1.68, 95%CI:
1.10, 2.58) remained independently predictive of attrition in the multivariate model. These var-
iables remained also significantly associated with attrition based on the alternative retention in
care estimates of 79.5% and 87.9%. Moreover, men were more likely to experience attrition
compared to women based on the 79.5% estimate (HR = 1.42; 95%CI: 1.02, 1.99).
Discussion
In this large multi-center study, the current retention in care estimate of 86% in the first 12
months of cART is in line with [21–23] or better than [12, 24–27] previous study findings from
other resource-limited settings. Similarly, retention in care was comparable with or even higher
than estimates from Europe or the USA [28–32] although strict comparison may not be appro-
priate as studies in these settings measured retention along the whole cascade of care from HIV
testing to viral load suppression [33–35]. However, our result is lower than the one year
nation-wide retention in care estimate of 92% in a recently published article from Ethiopia
[36]. The most likely explanation is the continuous influx and referral of severely immuno-
compromised patients to the health facilities in Addis Ababa for better treatment, who may
have died shortly after the start of cART, or simply returned back to their place of origin with-
out a formal transfer-out procedure.
The higher risk of attrition in the first 6 months of antiretroviral therapy, a period consid-
ered crucial for the long-term success of cART [37], is in agreement with previous reports from
Ethiopia [9, 10, 13] and other African countries [25, 37–39]. Notably, of the total number of
Fig 3. Kaplan-Meier survival curve for retention in HIV care by functional status at the start of cART, Addis Ababa, 2013 (n = 836).
doi:10.1371/journal.pone.0130649.g003
Retention in HIV Care and Predictors of Attrition in Addis Ababa
PLOS ONE | DOI:10.1371/journal.pone.0130649 June 26, 2015 9 / 15
Table 2. Results of the Cox regression model showing predictors of attrition from HIV care among HIV infected adults on cART.
Patient characteristic Retained in HIV care
(n = 684)
Not-retained in HIV
care(n = 152)
Univariate analysis
HR (95% CI)
Multivariate analysis
HR (95% CI)
Demographics
Agea, (n = 833)
18–24 yrs 42 (5.0%) 15 (1.8%) 1.58(0.93, 2.70)* 1.47(0.37, 1.08)
>24 yrs 639 (76.7%) 137 (16.4%) 1 1
Sexa, (n = 836)
Male 252 (30.1%) 72 (8.6%) 1.48(1.07, 2.03)* 1.32(0.94, 1.87)
Female 432 (51.7%) 80 (9.6%) 1 1
Educational statusa, (n = 795)
Tertiary 74 (9.3%) 12 (1.5%) 0.77 (0.38, 1.58)
Secondary 274 (34.5%) 56 (7.0%) 0.93 (0.56, 1.55)
Primary 230 (28.9%) 37 (4.7%) 0.76 (0.44, 1.32)
No education 92 (11.6%) 20 (2.5%) 1
Marital statusa, (n = 796)
Married or co-habiting 332 (41.7%) 49 (6.2%) 0.71 (0.46, 1.11)* 0.85(0.53, 1.36)
Divorced or separated 111 (13.9%) 25 (3.1%) 1.03 (0.61, 1.74) 1.23(0.69, 2.19)
Widowed 73 (9.2%) 20 (2.5%) 1.22 (0.69, 2.14) 1.51(0.80, 2.83)
Never married 154 (19.3%) 32 (4.0%) 1 1
Characteristics at enrolment in HIV care
HIV status disclosure (to family/closest
friend/ neighbor)a, (n = 836)
Yes 490 (58.6%) 82 (9.8%) 0.49 (0.35, 0.69)* 1.85(0.86, 3.95)
No 30 (3.6%) 10 (1.2%) 0.94 (0.48, 1.83) 0.83(0.54, 1.28)
Unknown 164 (19.6%) 60 (7.2%) 1 1
CD4 count (cells/μL)a, (n = 821)
Quartile1 (0–73) 148 (18.0%) 60 (7.3%) 3.33 (2.01, 5.53)* 3.03(1.76, 5.22)‡
Quartile2 (74–141) 170 (20.7%) 35 (4.3%) 1.77 (1.02, 3.06) 1.78(1.00, 3.16)‡
Quartile3 (142–239) 174 (21.2%) 30 (3.7%) 1.52 (0.87, 2.68) 1.51(0.83, 2.75)
Quartile4 (240–1,163) 184 (22.4%) 20 (2.4%) 1 1
Characteristics at cART initiation
Functional statusb, (n = 817)
Bed ridden 17 (2.1%) 10 (1.2%) 3.09(1.61, 5.93)* 2.22(1.10, 4.46) ‡
Ambulatory 81(9.9%) 32 (3.9%) 2.13(1.43, 3.17) 1.68(1.10, 2.58) ‡
Working 576(70.5%) 101 (12.4%) 1 1
WHO clinical stageb, c, (n = 830)
Stage IV 74 (8.9%) 25 (3.0%) 1.93(1.11, 3.34)* 0.61(0.33, 1.16)
Stage III 241 (29.0%) 68 (8.2%) 1.65(1.05, 2.59) 1.05(0.62, 1.78)
Stage II 201 (24.2%) 30 (3.6%) 0.92(0.54, 1.55) 0.88(0.44, 1.78)
Stage I 165 (19.9%) 26 (3.1%) 1 1
Evidence of tuberculosis at or after start
cART, (n = 817)
Yes 120 (14.7%) 31 (3.8%) 1.24 (0.84, 1.85)
No 552 (67.6%) 114 (14.0%) 1
First line drug regimenb, (n = 836)
d4T-containing 60 (7.2%) 20 (2.4%) 1.11 (0.68, 1.82)* 1.12(0.63, 2.02)
AZT-containing 275 (32.9%) 47 (5.6%) 0.64 (0.45, 0.92) 0.88(0.58, 1.34)
TDF-containing 349 (41.7%) 85 (10.2%) 1 1
Months since HIV diagnosisb, (n = 822)
(Continued)
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patients who were not retained in care, nearly half had died and the remaining 54% had
become LTFU. Previous studies in Africa have reported that AIDS-related causes including
mycobacterial and neurologic infections, malnutrition/anemia, drug toxicity, immune-
reconstitution inflammatory syndrome (IRIS), and septicemia may be the most likely causes
[22, 40–42]. In addition, a considerable number of the LTFU patients who were traced and
directly interviewed pointed out that they had run out of ARV medications while away from
home for different reasons. Therefore, the current practice of antiretroviral drug prescription
for 1 to 3 months in the routine follow-up care, or for 1 month as an emergency [20], needs to
be relaxed further to accommodate individual patient needs and special circumstances.
A sizable proportion of the LTFU patients who claimed to be “self-transferred” reported
that they re-started taking cART in the new facility as if they were naive. These kinds of prac-
tices have been reported previously [9, 43], and may have implications on ART program out-
come evaluations and resource allocation at the regional and/or national level [44]. An
additional issue to consider is the substantial proportion of LTFU patients whom we were
unable to trace because of reasons mainly related to incomplete, non-functioning or no
recorded contact address. Measures to strengthen the recording of accurate information with
alternative contact addresses at the enrolment of patients in HIV care are required at the facil-
ity level.
An interesting finding is that two-thirds of the HIV-infected patients had already been in a
state of advanced immune deficiency (i.e.<200 CD4 cells/μL) by the time they were enrolled
in HIV care. Severe immune deficiency of73 CD4 cells/μL at enrolment in care was found
to be the strongest predictor of attrition and adds to evidence of several other studies [25, 37,
44, 45]. As a strategy, the WHO and national treatment guidelines have been continuously
updated to raise the CD4 cell count threshold of initiating cART well above 200 cells/μL [20,
46, 47]. However, this initiative should be supported by identification and enrollment of
patients in care as early as possible [48, 49]. In addition, the causes of late enrolment in care
with advanced immunodeficiency in a setting where HIV counseling and testing is widely
available, and knowledge of where to get a HIV test is nearly 100% [50], should be further scru-
tinized and addressed.
This study has important strengths. The larger sample size coupled with the random selec-
tion of study facilities and patients facilitate generalization of the findings to adult patients
from urban areas. Moreover, meticulous ascertainment of LTFU patients’ current status in
HIV care via phone call tracing helped to better estimate the level of retention in care and
Table 2. (Continued)
Patient characteristic Retained in HIV care
(n = 684)
Not-retained in HIV
care(n = 152)
Univariate analysis
HR (95% CI)
Multivariate analysis
HR (95% CI)
1 month 377 (45.9%) 94 (11.4%) 1.29 (0.92, 1.79)
>1 month 295 (35.9%) 56 (6.8%) 1
a at enrolment in HIV care.
b at start cART.
c according to the revised World Health Organization clinical staging of HIV/AIDS for adults and adolescents, 2005 [51].
d4T, Stavudine; AZT, Zidovudine; TDF, Tenofovir.
HR, hazard ratio.
* p-value < 0.2.
‡ p-value < 0.05.
1 = reference category.
doi:10.1371/journal.pone.0130649.t002
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understand some of the reasons for attrition from the patients’ perspective, e.g., patients had
run out of ARV medications while away from home.
Results from this study should be interpreted cautiously. First, contact addresses for nearly
half of the LTFU patients were either missing or non-functioning. This might have underesti-
mated the true level of retention in care. Conversely, retention might also have been overesti-
mated because attrition (due to LTFU) was ascertained only once during the study period.
Since LTFU may occur more than once in the course of treatment for an individual patient,
patients classified as “retained in-care”may have previously been LTFU. Future studies may
need to prospectively ascertain patients’ status across the continuum of care for a better and
more refined estimate. Secondly, it is possible that LTFU patients’ responses might be affected
by perceived social desirability. Thirdly, the follow-up period in the present study is relatively
short and the results may not be applicable to longer follow-up periods. Finally, confounding
due to unmeasured characteristics can’t be ruled out.
In summary, the current retention in care estimate among HIV-infected adults receiving
cART in Addis Ababa is high and comparable with or even better than several previous study
results from resource-limited and resource-rich settings. However, early attrition from care
shortly after cART initiation is still a problem. Severe immune deficiency at enrolment in care/
or at cART initiation and poor functional status at start cART were important predictors of
attrition. Therefore, earlier identification of HIV-infected people and enrolling them in care as
early as possible should be part of future interventions.
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